MedTrace Logo

Pertussis Immunization During Pregnancy & HIV Infection

NCT03519373 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 135

Last updated 2024-12-03

No results posted yet for this study

Summary

The impact of chronic HIV infection and pregnancy on different aspects of the humoral response to pertussis immunization with the TDaP vaccine will be studied. The parameters will be measured in 3 groups (HIV-infected pregnant, HIV-uninfected pregnant and HIV-uninfected non pregnant) at different time points before and after immunization (7-10 days, 30 days and at delivery). The transfer ratio and the quality of maternal antibodies will be studied in cord blood.

Conditions

Interventions

BIOLOGICAL

TDaP

Tetanus, Diphteria and Acellular Pertussis vaccine (Boostrix)

Sponsors & Collaborators

  • Centre Hospitalier Universitaire Saint Pierre

    lead OTHER

Principal Investigators

  • Nicolas Dauby, M.D. Ph.D. · Centre Hospitalier Universitaire Saint Pierre

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2019-06-01
Completion
2019-06-01

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03519373 on ClinicalTrials.gov